<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01555008</url>
  </required_header>
  <id_info>
    <org_study_id>LX4211.1-107-DM</org_study_id>
    <secondary_id>LX4211.107</secondary_id>
    <nct_id>NCT01555008</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes Mellitus and Moderate to Severe Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study is intended to assess the pharmacodynamics (PD), pharmacokinetics (PK),
      safety and tolerability of LX4211 following once daily oral administration in subjects with
      type 2 diabetes mellitus (T2DM) and moderate to severe renal impairment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in postprandial glucose</measure>
    <time_frame>baseline to 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing an adverse event</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose</measure>
    <time_frame>baseline to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glucagon-like peptide 1 (Glp-1)</measure>
    <time_frame>baseline to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>Days 1 and 7; predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LX4211 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211</intervention_name>
    <description>Subjects will receive LX4211 once daily for 7 days</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211 Placebo</intervention_name>
    <description>Subjects will receive LX4211 placebo once daily for 7 days</description>
    <arm_group_label>LX4211 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 to ≤80 years of age

          -  History of T2DM for at least 6 months prior to screening

          -  Moderate to severe renal impairment and not actively on dialysis

          -  Willing and able to perform self-monitoring of blood glucose

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  History of type 1 diabetes mellitus, diabetic ketoacidosis (within the previous 6
             months), or diabetes resulting from pancreatic disorder or secondary diabetes (from
             acromegaly and/or Cushing's disease)

          -  Subjects who have received a renal allograft

          -  Subjects expecting to require dialysis or to undergo kidney transplantation within 3
             months of study dosing

          -  Presence of active hepatic disease or clinically significant abnormal liver function
             tests at Screening or planned study Day -1

          -  Subjects with a history of heart attack, severe/unstable angina, or coronary
             revascularization procedure within 6 months prior to study Day -2

          -  History of clinically significant cardiac arrhythmias within 1 year prior to study Day
             -2

          -  Subjects with congestive heart failure

          -  Subjects with uncontrolled Stage III hypertension

          -  History of 2 or more emergency room visits, doctors' visits, or hospitalizations due
             to hypoglycemia within the 6 months prior to planned study Day -2

          -  History of alcohol or illicit drug abuse within 1 year prior to Screening

          -  History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C

          -  Major surgery within 6 months prior to planned study Day -2

          -  History of any malignancy within the last 5 years

          -  Triglycerides &gt;1000 mg/dL at Screening or planned study Day -1

          -  History of any serious adverse reaction or hypersensitivity to an SGLT inhibitor

          -  Use of corticosteroids within 2 weeks prior to study Day 1

          -  Use of any investigational drug within 30 days prior to study Day 1, or
             investigational protein or antibodies within 60 days of Day 1

          -  Positive urine pregnancy test at Screening

          -  Positive urine screen for illicit drug abuse at Screening

          -  Prior exposure to LX4211
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ike Ogbaa, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <last_update_submitted>September 6, 2013</last_update_submitted>
  <last_update_submitted_qc>September 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

